Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Do China Start-ups Differ From The West?

This article was originally published in PharmAsia News

Executive Summary

During the annual ChinaBio conference in Shanghai, four top start ups – Ascletis, Aslan, BeiGene and Hua Medicine – discuss how their strategies in China differ from the traditional U.S. biotech model.


Related Content

Biopharma Out-licensing: 2012’s “In” Thing?
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
Merck Invests In China Oncology Start-up BeiGene
China And Taiwan Move Toward Clinical Data Mutual Acceptance, Regulatory Harmonization


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts